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Abstract
Background: Benzodiazepines (BZD) misuse is a serious public health problem, especially among opiate-
dependent patients with anxiety enrolled in methadone program because it puts patients at higher risk of life-
threatening multiple drug overdoses. Both elevated anxiety and BZD misuse increase the risk for ex-addicts to
relapse. However, there is no recent study to assess how serious the problem is and what factors are associated
with BZD misuse. This study estimates the prevalence of BZD misuse in a methadone program, and provides
information on the characteristics of BZD users compared to non-users.
Methods: An anonymous survey was carried out at a methadone program in Baltimore, MD, and all patients were
invited to participate through group meetings and fliers around the clinic on a voluntary basis. Of the 205 returned
questionnaires, 194 were complete and entered into final data analysis. Those who completed the questionnaire
were offered a $5 gift card as an appreciation.
Results: 47% of the respondents had a history of BZD use, and 39.8% used BZD without a prescription. Half of the
BZD users (54%) started using BZD after entering the methadone program, and 61% of previous BZD users reported
increased or resumed use after entering methadone program. Compared to the non-users, BZD users were more
likely to be White, have prescribed medication for mental problems, have preexistent anxiety problems before opiate
use, and had anxiety problems before entering methadone program. They reported more mental health problems in
the past month, and had higher scores in anxiety state, depression and perceived stress (p < .05).
Conclusions: Important information on epidemiology of BZD misuse among methadone-maintenance patients
suggests that most methadone programs do not address co-occurring anxiety problems, and methadone
treatment may trigger onset or worsening of BZD misuse. Further study is needed to explore how to curb misuse
and abuse of BZD in the addiction population, and provide effective treatments targeting simultaneously addiction
symptoms, anxiety disorders and BZD misuse.
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Background
Benzodiazepines (BZD) misuse and abuse is a serious
public health problem in the United States. This pro-
blem is especially pertinenta m o n gt h o s ew i t ho p i a t e
dependence [1] because these individuals are more likely
to experience elevated anxiety after stopping use of opi-
ates, with increased risk of using BZD as an anxiety cop-
ing strategy [2]. In addition, it has been shown that
individuals who abuse BZD are at increased risk of con-
tinuing opiate abuse [3]and failing to stay in methadone
treatment [4,5]. BZD use has also been shown to be
associated with use of multiple psychotropic drugs,
higher rates of depression and anxiety [6].
Benzodiazepines are psychoactive drugs used primarily
to treat anxiety and sleep disorders. Their intended uses
include anxiolytic, sedative hypnotic, anticonvulsant, and
muscle relaxant [7] therapy in low to medium doses.
They are central nervous system depressants and
research has shown that inappropriate use can result in
physical [8] and psychological dependence [9] and
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were initially developed and prescribed in small doses.
Over time they have come to be prescribed in larger
doses [7] which resulted in an increase in prescription
abuse and/or use without a prescription. These two pro-
blems have created a public health issue identified as
benzodiazepine misuse [7,11-14]
Benzodiazepine misuse and abuse are challenging to
define. Criteria used to define BZD dependence have
included: unsuccessful attempts to cut back or terminate
use, feeling uncomfortable when not taking BZD [9],
history of long-term use, and dosage escalation and high
anxiety levels despite taking BZD [1]. There are three 3
sub-populations who misuse BZD according to Ashton
[1]: (1) patients who are prescribed BZD therapeutically
for the short-term and take them for the long-term,e s t i -
mated at 4 million people in the U.S. and it is likely that
half of them are dependent; (2) patients who are pre-
scribed BZD therapeutically but then increase the dose
on their own by going to additional doctors or seeking
them out on the street (prevalence unknown), and (3)
patients who seek BZD for recreational use without a
prescription, which might represent a small proportion
of BZD abusers though at present there is no estimate
on the actual prevalence. This third group tends to be
poly-substance abusers and they seek BZD to enhance
the effects of other drugs, alleviate withdrawal effects of
other drugs, and to produce their own stimulating
effects taken alone or intravenously. For those who take
BZD for anxiety, the effects were reported to wear off
more quickly over time and individuals were more likely
to try higher doses or add other BZD to minimize dis-
comfort. It thus appears that continued BZD use does
not produce a reduction of anxiety, but rather, keeps
withdrawal symptoms at bay [1]
Busto et al. [15] found that BZD were the primary
drug of abuse in 32% of the multiple drug abusers.
Anecdotal reports from our clinical observations and
counselor feedback seem to indicate that a large propor-
tion of patients on methadone maintenance use BZD
without a prescription (misuse). Lankenau et al. [16]
noted increases in prescription drug misuse including
BZD among patients of a methadone program. Their
findings suggested that BZD misuse might be associated
with increased use of other illegal drugs and drug
dependency and suggested increased street outreach as a
method to address this problem. However, due to lack
of education regarding monitoring techniques for physi-
cians and inaccurate reporting [17] from patients, a
comprehensive grasp of this problem has been elusive.
It seems that anxiety could be the primary motivation
for this misuse but there are few studies at this time to
develop a comprehensive picture of this social and
health problem. A PUBMED search using keywords
“benzodiazepine abuse” and “opiate” revealed only seven
studies conducted in the past twenty years [3,5,6,18-21].
Therefore, it seems that there is a discrepancy between
clinical reports of BZD misuse and research investiga-
tion of the problem, particularly in the United States.
There has been little recent research into BZD use
among methadone maintenance patients in the United
States. Small studies were conducted during the 1980s
and 1990s but need updating due to the changing
demographics and patterns of drug use. Gelkopf et al.
[22] examined BZD abuse in methadone maintenance
patients in a one-year prospective study in an Israeli
clinic and found that lifetime prevalence of BZD abuse
was 66.3% and current prevalence of BZD abuse was
50.8%. This study indicates that BZD abuse seems to be
a problem for heroin addicts both before entering and
during their methadone treatment.
This study is among the few in the U.S. [23] that clo-
sely examines BZD use and misuse among methadone-
maintained patients and was conducted to provide more
current data. These data will provide the background
information necessary to develop more acceptable and
effective therapies for the treatment of BZD misuse in
opiate dependent patients in the future.
The main purposes of this survey study are: 1) to esti-
m a t et h ep r e v a l e n c eo fB Z Du s ea n dm i s u s ea m o n g
patients in a methadone program; 2) to determine the
main reasons for their BZD use or misuse, to evaluate
whether the methadone treatment was a trigger for new,
increased or resumed use of BZD; 3) to examine the
characteristics of BZD users that may differentiate them
from other opiate-dependent patients, and 4) to assess
what proportion of BZD users are willing to accept
treatment if it were available.
Methods
Study Setting and Subjects
The survey was conducted at a methadone treatment
program in Baltimore city. This program is a part of the
University of Maryland Medical Center. The program
provides methadone maintenance services to about 500
insured and uninsured (mainly grant-funded) patients
who were the targeted population for this anonymous
survey.
All patients enrolled in the treatment program
between December 2009 and July 2010 were eligible to
participate in the study. Participation was voluntary, and
the instructions on the first page of the survey instru-
ment asked participants not to write their name any-
where on the questionnaire. Each participant who
completed the questionnaire was offered a $5 gift card
as an appreciation for their participation. Measures were
taken to ensure that the same participant did not fill out
the survey twice.
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The most effective way to reach all patients in such a
c l i n i cm a yb et ol e tt h ec o u n s e l o r sg i v et h eq u e s t i o n -
naire to each client in their caseload. However, since
patients who used BZD were often given negative conse-
quences (such as increased counseling or removal of
take-home privileges) we were concerned that patients
might not answer the questionnaire truthfully if they
thought, despite our assurance to the contrary, that
their counselor might find out their response to the
study questions. We therefore took special measures to
minimize the program counselors’ involvement in data
collection. We mainly used two methods of recruiting
patients into this survey: (1) we collaborated with the
clinic counselors to attend their weekly group meetings
and asked all patients in each group to participate in the
20-30 minute survey on a voluntary basis. The counse-
lors left the room during study administration while our
research staff supervised the questionnaire administra-
tion and answered questions. (2) For those patients who
did not attend any group meetings for various reasons,
we set up two one-hour walk-in study sessions a week
in the clinic and posted fliers around the clinic to invite
patients to participate in a study on their health status.
We avoided listing BZD in the fliers so as to circumvent
patient concerns about revealing their BZD use status.
Meanwhile, the counselors were asked to send those
patients who did not attend group meetings to these
study sessions. Study participation was open to all
patients regardless of any history of BZD use to prevent
inadvertent identification of BZD users due to their
volunteering to participate in the study. A research staff
member was there to supervise the questionnaire
administration and answer questions.
To make sure that patients understood what BZD are,
we gave the following specific instructions on the first
page: “Benzodiazepines, known as Benzos, are tranquili-
zer pills that are prescribed by doctors for treating
stress, nerves, anxiety or sleeping problems. Other
names may include Valium, Xanax, Librium, Ativan,
Klonopin, nerve pills, etc. You may know them as pins,
bars, or footballs. A list of names and pictures are avail-
able if you are not sure what Benzos are. You are invited
to participate even if you have never used Benzos.”
Since this was a minimum-risk anonymous survey,
participation was completely voluntary, and no name or
any other identifiers appeared on the study form, the
study was approved by University of Maryland Baltimore
institutional review board (IRB) for a waiver of informed
consent.
The Questionnaire
Based on some observations and meetings with counse-
lors, we developed a 5-page questionnaire assessing
basic demographics, substance use, and the health issues
related to our study aims. The key questions related to
BZD use included: what were the main reasons you first
began to use opiates? Have you ever used any benzodia-
zepines? Was your initial BZD use a prescription from
your doctor(s)? Have you ever used any BZD without a
prescription? What were the reasons you started to use
BZD that were not prescribed to you in the first place?
Did you use any BZD before you entered the methadone
program? Did your BZD use increase or start after com-
ing to the methadone program? How many days did
you use any BZD in the past 30 days? (The actual Ques-
tionnaire is available upon request)
In order to understand the possible differences in psy-
chological profile between BZN users and non-users, we
also included a few standard self-report psychological
assessments like the Spielberger State Anxiety Inventory
[24], Anxiety Sensitivity Index [25], CES depression
scale [26] and Perceived Stress Scale [27]. We hypothe-
sized that BZN users might have a different psychologi-
cal profile from the non-users, which should be
reflected in their mood, anxiety and perceived stress in
life. We tried to minimize the number of psychological
scales in such a quick survey to ensure reliability of the
answers.
Statistical Analysis
All data analyses were conducted using SPSS for Win-
dows (version 18). The population was described using
frequency analyses. Cross-tabulations for categorical
variables, and ANOVA for continuous variables, were
performed between each predictive variable according to
BZD use status to examine the possible differences.
Pearson’s Chi square tests for categorical variables, and
F tests in ANOVA for continuous variables, were calcu-
lated. Multivariable logistic regression modeling was
performed to examine the significant predictors (corre-
lates) of BZD use with control for other possible
confounders.
Results
Basic demographics and substance use
We collected a total of 205 returned questionnaires; 194
of them were judged to meet a minimum completion
threshold and were included in the final data analysis.
To evaluate the possible selection bias of our sample,
we compared the demographic characteristics of our
sample (n = 194) with the total patient population at
the methadone clinic (n = 485 by the end of 2010). Of
the 194 participants in our sample, 43.3% were female
(compared to 39.0% in the total patient population);
21.9% were white or Caucasian (25.9% in the total
patient population), 75.9% Black or African American
(69.9% in the total patient population). The
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cant between our sample and the total methadone pro-
gram population, suggesting that there was very little
evidence of selection bias in this survey study. In addi-
tion, 28.3% of survey participants were currently married
or living with a partner, 47.6% never married; 79.1% had
education level of high school diploma or less; 67.8%
had at least one child (75% of them have multiple chil-
dren); 12.5% of them hold a full-time job and another
12.5% had a part-time job, 35.9% were unemployed, and
28.3% had a disability income. Most participants consid-
ered themselves religious (90%); 35.5% of respondents
considered their treatment prompted or suggested by
criminal justice system or a court (20% were actually on
parole or probation). Participants’ age ranged from 17 to
83 years old, with a mean of 46.6 years, and median age
at 47 (which was comparable to the median age of 48 in
the total patient population).
Forty-three percent of respondents reported some form
of chronic medical problem that continued to affect their
life; 31% took some prescribed medications on a regular
basis for a physical health problem, and 30% took medi-
cations for mental or emotional problems (including
anxiety and depression). About 48% of respondents
reported having some form of anxiety or sleeping pro-
blems before they started using opiates/heroin; and
61.5% felt that they had some form of anxiety or sleeping
problems before entering the methadone program, which
could be the basis for their subsequent BZD use.
Benzodiazepines use and misuse
Of the 191 respondents who answered the question on
BZD use, 90 (47%) reported using BZD with or without
ap r e s c r i p t i o n .O ft h e9 0r e s p o n d e n t sw h oe v e ru s e d
BZD, only 25% said that their initial use began with a
prescription; 84% of them acknowledged ever using
BZD without a prescription (misuse) (some of them
started BZD use with a prescription, but used it later
without a prescription). Therefore, of the total effective
sample, 39.8% or 76 respondents reported ever using
BZD without a prescription. The main reasons they
gave for using BZD without a prescription are listed in
Table 1. Curiosity was the most common reason (46%),
followed by relieving tension or anxiety (41%) and feel-
ing good (37%).
Among the BZD users, 54% did not start using BZD
until after entering the methadone program. The mean
age of onset into BZD use was around 31 years old. Of
those who used BZD before entering the methadone
program, 61% reported that their BZD use increased or
restarted after entering the methadone program.
Although 78% of BZD users did not acknowledge their
BZD use as a problem at the moment, 56% of them had
tried to stop using BZD at least once (28% of them tried
to stop using BZD more than once, and 14% had
entered in a BZD detoxification program). We asked the
respondents if they would consider reducing or stopping
use of BZD if we could provide help that will work; 40%
said “Yes, definitely”,7 %s a i d“Maybe”,a n do n l y1 9 %
said “No” (33% had stopped using BZD already).
Differences between BZD-users and non-users
Table 2 presents differences between BZD-users and
non-users in this survey sample. Among those notice-
able differences, BZD users were more likely to be of
White or Caucasian race (35% vs. 11%, p < .01), have
lower self-reported religiosity on the 1–10 scale (6.2 vs.
7.1, p < .01), and feel less healthy (35% vs. 48%; p < .05).
Compared to non-users, BZD users were more likely to
have been prescribed medication for mental or emo-
tional problems (49% vs. 22%, p < .01), had anxiety pro-
blems before use of opiates (61% vs. 37%, p < .01), and
h a da n x i e t yo rs l e e pp r o b l e m sb e f o r ee n t e r i n gt h e
methadone program (78% vs. 48%, p < .01). They
reported more days with mental or emotional problems
in the past 30 days (10.4 vs. 6.3), and higher scores in
all four psychological measures – anxiety sensitivity,
anxiety state, depression and perceived stress (p < .05).
We further examined the differences in reasons given
for initiation of opiate use, and discovered that the pri-
mary reason given by non-users was curiosity (59%), fol-
lowed by social reasons (55%), whereas the number one
reason for opiate use given by current BZD-users was
“for pleasure or to get high” (67%), followed by social
reason (63%). A significantly higher proportion of BZD
users indicated both for pleasure or to get high (67% vs.
44%, p < .01) and to relieve negative mood (57% vs.
34%, p < .05) as reasons for opiate use compared to
non-users. We also asked the respondents to check the
Table 1 List of the main reasons for starting misuse of
BZD
The reasons for initial use of opiates N %
Curious to see what it’s like 41 45.6
To relax or relieve tension/anxiety 37 41.1
To feel good 33 36.7
To get high 22 24.4
To overcome depression or frustration 21 23.3
To get away from my problem or troubles 18 20.0
To have a good time with my friends 13 14.4
To go along with what my friends are doing 9 10.0
It’s something my friends do when we get together 7 7.8
To fit in with a group I like 6 6.7
To produce intense, exciting experience 6 6.7
To rebel against my parent(s) 3 3.3
Never used non-prescribed BZD 8 8.9
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Table 3, BZD users tended to report more negative
effects of opiates than non-users by endorsing state-
ments such as “feel tired and unhealthy”, “do not want
to go to work” and “cannot stay focused.”
To systematically examine the significant correlates of
BZD use with control for possible confounders, we
applied a logistic regression model with BZD-use status
as the dependent variable and the possible significant
correlates (see Table 2) as the independent variables
(predictors). With the method of backward deletion in
the multivariate logit model, four significant correlates
that predict BZD usage status (see Table 4 for details)
were revealed. They were White race, anxiety problem
before entering methadone program, use of opiates for
pleasure or to get high, and high depression score. The
model explains 26% of variance (R
2).
Table 2 Comparison of Main Demographics and Health History Between BZD Users and Non-Users in the Methadone
programs
Variables Non-Users
(n ≤ 101)
BZN-Users
(n ≤ 90)
p ≤
a
Demographics
% female 40.4% 48.1% .442
Mean age (SD) 47.5 (7.1) 45.4 (10.3) .107
% of White/Caucasian 11.1% 35.3% .001
% of Single (never married) 53.5% 42.7% .369
Religiosity (1–10 scale) 7.12 (1.9) 6.17 (2.3) .003
Health Issues
General Health Status
➤ Poor
➤ Ok, but below average
➤ Fair
➤ Good
➤ Excellent
7.1
11.1
33.3
45.5
3.0
1.1
26.1
37.5
31.8
3.4
.017
% had chronic medical problems 36.7% 47.5% .153
% ever had prescribed med for mental Or emotional problems 21.6% 40.0% .007
% have had anxiety or sleeping problems before starting use of opiates/heroin 36.8% 61.2% .005
% have had anxiety or sleeping problems before entering methadone program 48.4% 78.3% .001
Age of onset into alcohol use 16.5 (6.5) 14.9 (4.6) .073
Age of onset into opiate/heroin use 23.5 (7.7) 21.7 (7.5) .120
Age first admitted to a methadone program 37.1 (15.3) 35.3 (11.3) .387
# of days with mental or emotional problems In the past 30 days 6.28 (9.9) 10.4 (11.6) .048
Psychological Measurements
Anxiety sensitivity - physical score 7.94 (6.1) 8.96 (5.4) .231
Anxiety sensitivity - cognitive score 4.68 (5.4) 6.54 (5.4) .020
Anxiety sensitivity - social score 5.78 (5.2) 6.98 (5.1) .115
Anxiety sensitivity - Total score 18.4 (15.1) 22.4 (13.7) .058
Perceived Stress Scale 15.6 (8.2) 18.6 (7.4) .011
CES Depression scale 37.8 (10.4) 42.7 (8.5) .001
Spielberg Anxiety State score 40.9 (11.6) 44.4 (10.6) .036
a. P values are from chi-square test for categorical variables in contingency table, and F test continuous variables in ANOVA.
Table 3 Noticed Side Effects after Using Heroin/Opiates
by BZD Use Status (Among those who answered the
question N = 181)
Noticed Side Effects of
Opiate Use
Non-
Users
(n = 93)
Past-
Users
(n = 41)
Current-
Users
(n = 47)
p ≤
Cost me too much
money
66.7% 85.4% 66.0% .064
Feel tired and unhealthy 25.8% 31.7% 46.8% .043
Feel sleepy most of time 20.4 12.2 21.3 .467
Loss of interest in sex 31.2 31.7 40.4 .525
Do not want to go to
work
21.5 24.4 42.6 .027
Loss of appetite 34.4 41.5 36.2 .736
Cannot stay focused 12.9 31.7 40.4 .001
Feel anxious or edge 22.6 36.6 40.4 .059
Not at all 14% 5% 10.6% .300
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dictors so that they could not be significant in the
model simultaneously. For example, “use opiates for
relieving tension or anxiety” was also a significant pre-
dictor (p < .05) if the predictor “use opiate for pleasure
or to get high” was removed, which supports the
assumption that BZD use could be the result of coping
with stress and anxiety during methadone maintenance.
Discussion
This cross-sectional survey study offered us answers to
most of the research questions we asked for this study.
First, we wanted to estimate the prevalence of BZD use
and misuse among patients in a methadone program, and
the survey revealed a prevalence of 47% lifetime use of
BZD among our methadone-maintained patients, and
most of whom used BZD without a prescription (39.8%
of the survey respondents). This prevalence is lower than
that reported in European countries [4,6]. This was likely
due in part to the fact that our methadone maintenance
program had a policy that no BZD use was allowed.
Second, we wanted to determine the main reasons for
their BZD use or misuse, to evaluate whether the metha-
done treatment was a trigger for new, increased or
resumed use of BZD; The survey shows that the main rea-
sons for using BZD without a prescription are curiosity
(46%), relieving tension or anxiety (41%) and feeling good
(37%). Of all the self-reported BZD users, half (54%) did
not use BZD until after they entered into methadone pro-
gram, and 61% of previous BZD users reported increased
use or resumption of use after entering the methadone
program, which suggests a need for further research into
reason for high prevalence of anxiety problems and BZD
misuse in methadone-maintained patients.
Third, we wanted to examine the characteristics of
BZD users that may differentiate them from other opi-
ate-dependent patients, Our study revealed that, com-
pared to those methadone-maintenance patients who
n e v e ru s e dB Z D ,B Z Du s e r sw e r em o r el i k e l yt ob e
White or Caucasian, have lower religiosity, have been
prescribed medication for mental problems, have anxiety
problems before entering the methadone program, and
have preexistent anxiety problems before use of opiates.
At the time of survey, they reported more number of
days with mental or emotional problems in the past
month, and higher scores in anxiety state, depression
and perceived stress (p < .05).
Fourth, we wanted to assess what proportion of BZD
users are willing to accept treatment if it were available.
We did ask a question at the end of survey, “Do you
intend to reduce or stop your use of Benzos if we can
provide help that will work?” Among those who are cur-
rent BZD users, 60% answered “Yes, definitely”,a n o t h e r
11% said they may try. Only 29% said they were not
interested in stopping BZD use.
This is one of the few studies of its kind in the United
States, and the first to provide data from a contemporary
methadone maintenance population, especially on the
possible characteristic differences between BZD-user and
non-users, and on the possible impact of methadone
treatment itself on the BZD use by opiate-dependent
patients. There are several limitations in this study and
caution is needed when interpreting the results and their
implications. First, this is a cross-sectional survey, and
causal relationships cannot be drawn from any of the
data. Second, due to the specific research design in data
collection, we might have missed two groups from the
clinic. Namely, those with serious poly-drug use, mental
health problems who might not attend any groups regu-
larly and who may not want to reveal their problems in a
study like this, and those who had take-home medication
privileges of more than a week who would not need to
come for frequent groups or to the clinic during the
hours of our study sessions. These two groups repre-
sented two poles of this treatment population, and it is
likely that they were under-represented in this survey.
Third, it is not possible to determine any clinical diag-
noses of co-occurring mental disorders through a survey
like this; therefore, this study cannot establish a connec-
tion between BZD use and co-occurring mental disor-
ders, even though it is possible that there may be such an
association. It is also not clear from this survey if the
apparent new onset of BZD use after starting methadone
maintenance is intrinsically related to the treatment itself
Table 4 Coefficients in Logistic Regression of Significant Predictors for BZD Use (Among those who had a valid
responses to all related questions n = 184)
Predictors Beta s,e, Odds ratio p ≤
(Constant) -3.357 0.805 .001
White (vs. Black and others) 1.001 0.423 2.72 .026
Had anxiety or sleeping problem before entering methadone program 0.867 0.341 2.38 .011
Used opiates for pleasure or get high 0.963 0.335 2.62 .004
CES Depression score 0.048 0.018 1.05 .007
Model Chi-square 39.27 (df = 5) .001
Nagelkerke R
2 0.257
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mental factor such as increased association with other
users and greater access to BZD.
Conclusion
Despite these limitations, this survey study provides us
with important information on the epidemiology of BZD
use and misuse among methadone-maintenance
patients. The study findings suggest that most metha-
done programs do not address co-occurring anxiety pro-
blems, and methadone treatment may trigger onset or
worsening of BZD misuse.
Additionally, our findings shed light on the factors or
correlates associated with BZD use by methadone main-
tenance patients. Further study is needed to explore
ways to curb the use and abuse of prescription drugs
like BZD in this population, and to develop effective
treatments that will simultaneously target addiction
symptoms, anxiety disorders, and BZD misuse.
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